Document Detail


Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization.
MedLine Citation:
PMID:  19436654     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Coronary stent thrombosis is a serious problem in the drug-eluting stent era. Despite aggressive antiplatelet therapy during and after percutaneous coronary intervention (PCI), the incidence of sub-acute stent thrombosis remains approximately 0.5%-2%, which may represent a catastrophic clinical situation. Both procedural factors and discontinuation of antiplatelet therapy are normally associated with this event. We report on simultaneous stent thromboses of two drug-eluting stents implanted in two different vessels, which resulted in a life-threatening clinical condition. Possible contributing factors that led to synergistic thrombotic effects are discussed.
Authors:
Clarissa Cola; Salvatore Brugaletta; Victoria Martín Yuste; Bieito Campos; Dominick J Angiolillo; Manel Sabaté
Related Documents :
16133694 - Percutaneous transhepatic gallbladder stenting for recurrent acute acalculous cholecyst...
14569324 - Coronary stent graft for hypertrophic obstructive cardiomyopathy combined with coronary...
19786634 - Final 5-year results of the taxus ii trial: a randomized study to assess the effectiven...
20236214 - Two-year clinical registry follow-up of endothelial progenitor cell capture stent versu...
8835424 - Cyclic phenomena in early myocardial infarction.
15799914 - Endoscopic radial artery harvest for coronary artery bypass grafting: initial clinical ...
Publication Detail:
Type:  Case Reports; Journal Article; Review     Date:  2009-04-08
Journal Detail:
Title:  Vascular health and risk management     Volume:  5     ISSN:  1178-2048     ISO Abbreviation:  Vasc Health Risk Manag     Publication Date:  2009  
Date Detail:
Created Date:  2009-05-13     Completed Date:  2009-06-19     Revised Date:  2013-06-02    
Medline Journal Info:
Nlm Unique ID:  101273479     Medline TA:  Vasc Health Risk Manag     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  101-19     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Interventional Cardiology Unit, Sant Pau University Hospital, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Balloon, Coronary / adverse effects*,  instrumentation
Aspirin / therapeutic use
Cardiovascular Agents / administration & dosage
Coronary Angiography
Coronary Stenosis / etiology,  radiography,  therapy*
Coronary Thrombosis / etiology*,  radiography,  therapy
Diabetes Mellitus, Type 2 / complications*
Drug-Eluting Stents
Female
Humans
Medication Adherence
Middle Aged
Myocardial Infarction / etiology,  radiography,  therapy*
Platelet Aggregation Inhibitors / therapeutic use
Risk Factors
Sirolimus / administration & dosage
Ticlopidine / analogs & derivatives,  therapeutic use
Treatment Outcome
Chemical
Reg. No./Substance:
0/Cardiovascular Agents; 0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin; 53123-88-9/Sirolimus; 55142-85-3/Ticlopidine; A74586SNO7/clopidogrel
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Alveolar dead space and capnographic variables before and after thrombolysis in patients with acute ...
Next Document:  Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil.